Expert Interviews

Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.

Daniel Pollyea, MD, MS, discusses how he assesses patients with newly diagnosed acute myeloid leukemia for the best first-line therapy, including the role of intensive induction chemotherapy.

Eunice S. Wang, MD, offers an overview of common barriers to performing molecular testing in community practices, including uncertainty about which tests to perform and the wait times for results.

Focused discussion on the safety and efficacy data from MonumenTAL-1, which utilized talquetamab monotherapy in patients with relapsed/refractory multiple myeloma.

Following a brief review of the relapsed/refractory multiple myeloma treatment landscape, Carolina Schinke, MD, provides an overview of the MonumenTAL-1 study design.

In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.

The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.

Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.

The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.

Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.

Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.

Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Expert perspectives on ensuring the early detection and treatment of CRS and other adverse events when initiating bispecific therapy in patients with multiple myeloma.

Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.

Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.

Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.

A panel of experts shares insight on treatment sequencing and selection in the setting of relapsed/refractory multiple myeloma.

Experts from Ochsner Health highlight treatment options for patients who present with transplant-ineligible newly diagnosed multiple myeloma.

Experts on multiple myeloma discuss the management of adverse effects from bispecific antibodies.

Experts on multiple myeloma offer clinical insights on treatment options and considerations for patients with standard- and high-risk multiple myeloma.